|Day Low/High||4.15 / 4.56|
|52 Wk Low/High||2.00 / 14.98|
Struggling Mass. biotech firm Epix Pharmaceuticals explores strategic options, including sale
Epix Pharmaceuticals may file for bankruptcy protection; offers cash and stock for debt
It may be best to wait for data from two clinical studies on Alzheimer's drug PRX-03140 before making any predictions about its prospects.
A wild day leaves major averages slightly higher. James Bianco opines on the credit crunch, and Dan Fitzpatrick on the search for Santa.
Adobe rises on earnings; iRobot shares salute Army contract.
Epix Pharmaceuticals sinks 15.6% on disappointing study results of its experimental anxiety drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.